Applied Pharmacology:
Medications (Other Than Buprenorphine) Used to Treat Opioid Addiction

Ball JC and Ross A. The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York, 1991, pp. 166–168, 181–182.

Camí J, de Torres S, San L, Solé A, Guerra D, and Ugena B. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics (38):336–341, 1985.

Charney DS, Sternberg DE, Kleber HD, Heninger GR, and Redmond DE. The clinical use of clonidine in abrupt withdrawal from methadone. Archives of General Psychiatry (38):1,273–1,277, 1981.

Cheskin LJ, Fudala PJ, and Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence (36):115–121, 1994.

Dole VP and Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. Journal of the American Medical Association (193):80–84, 1965.

Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, and Johnson RE. Dose-related efficacy of levo-alpha acetyl methadol for treatment of opioid dependence: A randomized clinical trial. Journal of the American Medical Association (277):1,945–1,951, 1997.

Finkle BS, Jennison TA, Chinn DM, Ling W, and Holmes ED. Plasma and urine disposition of l-alpha-acetylmethadol and its principal metabolites in man. Journal of Analytical Toxicology (6):100–105, 1982.

Fraser HF, Isbell H. Actions and addiction liability of alpha-acetylmethadols in man. Journal of Pharmacology and Experimental Therapeutics (105):458–465, 1952.

Freedman RR and Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug and Alcohol Dependence (8):215–222, 1981.

Gold MS, Redmond DE, and Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet September 16, 1978.

Gordon NB. Reaction times of methadone-treated ex-heroin addicts. Psychopharmacology (16):337–344, 1970.

Gordon NB, Warner A, and Henderson A. Psychomotor and intellectual performance under methadone maintenance. In: Committee on Problems of Drug Dependence, Minutes of the 29th Meeting of the National Academy of Sciences. Washington, DC: National Academy of Sciences, 1967.

Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence (21):253–259, 1988.

Grabowski J, O'Brien CP, Greenstein R, Ternes J, Long M, and Steinberg-Donato S. Effects of contingent payment on compliance with a naltrexone regiment. American Journal of Drug and Alcohol Abuse (6):355–365, 1979.

Gritz ER, Shiffman SM, Jarvik ME, Haber J, Dymond AM, Coger R, Charuvastra V, and Schlesinger J. Physiological and psychological effects of methadone in man. Archives of General Psychiatry (32):237–242, 1975.

Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, and Ginzburg HM. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, NC: University of North Carolina Press, 1989.

Jaffe JH, Schuster CR, Smith BB, and Blachley PH. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: A pilot study. Journal of the American Medical Association (211):1,834–1,836, 1970.

Jaffe JH and Senay EC. Methadone and l-methadyl acetate: Use in management of narcotic addicts. Journal of the American Medical Association (216):1,303–1,305, 1971.

Jaffe JH, Senay EC, Schuster CR, Renault PR, Smith B, and DiMenza S. Methadyl acetate versus methadone: A double-blind study in heroin users. Journal of the American Medical Association (222):437–442, 1972.

Jasinski DR, Johnson RE, and Kocher TR. Clonidine in morphine withdrawal: Differential effects on signs and symptoms. Archives of General Psychiatry (42):1,063–1,066, 1985.

Jones HE, Strain EC, Bigelow GE, Walsh SL, Stitzer ML, Eissenberg T, and Johnson RE. Induction with LAAM: Safety and efficacy. Archives of General Psychiatry (55):729–736, 1998.

Judson BA and Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts: I. Dosage schedule for induction and stabilization. Drug and Alcohol Dependence (4):461–466, 1979.

Judson BA, Goldstein A, and Inturrisi CE. Methadyl acetate (LAAM) in the treatment of heroin addicts: II. Double-blind comparison of gradual and abrupt detoxification. Archives of General Psychiatry (40):834–840, 1983.

Karp-Gelernter E, Savage C, and McCabe OL. Evaluation of clinic attendance schedules for LAAM and methadone: A controlled study. International Journal of Addictions (17):805–813, 1982.

Keats AS and Beecher HK. Analgesic activity and toxic effects of acetylmethadol isomers in man. Journal of Pharmacology and Experimental Therapeutics (105):210–215, 1952.

Kleber HD, Gold MS, and Riordan CE. The use of clonidine in detoxification from opiates. Bulletin on Narcotics (32):1–10, 1980.

Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. Journal of the American Medical Association (223):665–668, 1973.

Kreek MJ, Dodes L, Kane S, Knobler J, and Martin R. Long-term methadone maintenance therapy: Effects on liver function. Annals of Internal Medicine (77):598–602, 1972.

Ling W, Charuvastra C, Kaim SC, and Klett J. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Archives of General Psychiatry (3):709–720, 1976.

Ling W, Klett J, and Gillis RD. A cooperative clinical study of methadyl acetate: I. Three-times-a-week regimen. Archives of General Psychiatry (35):345–353, 1978.

Marcovici M, O'Brien CP, McLellan AT, and Kacian J. A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction. American Journal of Psychiatry (138):234–236, 1981.

McLellan AT, Arndt IO, Metzger DS, Woody GE, and O'Brien CP. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association (269):1,953–1,959, 1993.

McMahon RE, Culp HW, and Marshall FJ. The metabolism of alpha-dl-acetylmethadol in the rat: The identification of the probable active metabolite. Journal of Pharmacology and Experimental Therapeutics (149):436–445, 1965.

Mello NK, Mendelson JH, Kuehnle JC, and Sellers MS. Operant analysis of human heroin self-administration and the effects of naltrexone. Journal of Pharmacology and Experimental Therapeutics (216):45–54, 1981.

National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Archives of General Psychiatry (35):335–340, 1978.

Newman RG and Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet September 8, 1979.

Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment (10):391–394, 1993.

Parrino MW. State Methadone Treatment Guidelines, Treatment Improvement Protocol (TIP) Series, Number 1. Rockville, MD: Center for Substance Abuse Treatment, 1993.

Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, and Morley JE. Naltrexone hydrochloride (Trexan): A review of serum transaminase elevations at high dosage. In: Harris L (ed.). Problems of Drug Dependence 1985, Proceedings of the 47th Annual Scientific Meeting, The Committee on Problems of Drug Dependence. Research Monograph 67. Rockville, MD: National Institute on Drug Abuse, 1986.

Rettig RA and Yarmolinsky A (eds). Federal Regulation of Methadone Treatment. Washington DC: Institute of Medicine, National Academy Press, 1995.

Rounsaville BJ, Kosten T, and Kleber H. Success and failure at outpatient opioid detoxification: Evaluating the process of clonidine- and methadone-assisted withdrawal. Journal of Nervous Mental Disorders (173):103–110, 1985.

Savage C, Karp EG, Curran SF, Hanlon TE, and McCabe OL. Methadone/LAAM maintenance: A comparison study. Comparative Psychiatry (17):415–424, 1976.

Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, and Kosten TR. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry (54):713–720, 1997.

Senay EC, Dorus W, Goldberg F, and Thornton W. Withdrawal from methadone maintenance: Rate of withdrawal and expectations. Archives of General Psychiatry (34):361-–67, 1977.

Senay EC, Dorus W, and Renault PF. Methadyl acetate and methadone: An open comparison. Journal of the American Medical Association (237):138–142, 1977.

Spencer L and Gregory M. Clonidine transdermal patches for use in outpatient opiate withdrawal. Journal of Substance Abuse Treatment (6):113–117, 1989.

Strain EC and Stitzer ML (eds.). Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Methadone dose and treatment outcome. Drug and Alcohol Dependence (33):105–117, 1993.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Outcome after methadone treatment: Influence of prior treatment factors and current treatment status. Drug and Alcohol Dependence (35):223–230, 1994.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Randomized controlled trial of moderate versus high dose methadone in treatment of opioid dependence. Journal of the American Medical Association (281):1,000–1,005, 1999.

Tilly J, O'Brien CP, McLellan AT, Woody GE, Metzger DS, and Cornish J. Naltrexone in the treatment of federal probationers. In: Harris L (ed.). Problems of Drug Dependence 1991, Proceeding of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence. NIDA Research Monograph 119. Rockville, MD: National Institute on Drug Abuse, 1992.

Walsh SL, Sullivan JT, Preston KL, Garner JE, and Bigelow GE. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. Journal of Pharmacology and Experimental Therapeutics (279):524–538, 1996.

Ward J, Mattick RP, and Hall W. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Australia: Harwood Academic Publishers, 1998.

Washton AM and Resnick RB. Clonidine for opiate detoxification: Outpatient clinical trials. American Journal of Psychiatry (137):1,121–1,122, 1980.

Washton AM, Gold MS, and Pottash AC. Successful use of naltrexone in addicted physicians and business executives. Advances in Alcohol and Substance Abuse (4):89–96, 1984.